Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic Expands Global Presence with Participation in Key Industry Events
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.